Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1297572 | 0.87 | CHRM2 (0.48) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL2693319 | 0.85 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL7191976 | 0.85 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL8384596 | 0.85 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL2693326 | 0.85 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL23921599 | 0.85 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL7079357 | 0.85 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL2691303 | 0.85 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL1297620 | 0.82 | PPM1B (0.48) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL27398545 | 0.82 | CHRM2 (0.44) | CHRM2CHRM4CHRM3CYP2C19SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017024319-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024318-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017007612-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016105518-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |